Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5-Reference-Cited by-同舟云学术

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5

Published:2024-03-04 Issue:1 Volume:36 Page:31-38
ISSN:1863-5490
Container-title:Medizinische Genetik
language:en
Short-container-title:

Author:

Kühn Constanze¹^ORCID,Hörst Katharina¹^ORCID,Kvasnicka Hans M.²^ORCID,Hochhaus Andreas³^ORCID,Reiter Andreas⁴^ORCID

Affiliation:

1. MLL – Munich Leukemia Laboratory Munich Germany

2. University Hospital Institute for Pathology and Molecular Pathology Wuppertal Germany

3. Universitätsklinikum Jena Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II Jena Germany

4. III. Medizinische Klinik Medical Clinic for Haematology and Oncology, University Medical Centre Mannheim Mannheim Germany

Abstract

Abstract Within the World Health Organization (WHO) classification of haematopoietic neoplasms, particularly its fifth version from 2022 (WHO-HAEM5), myeloid neoplasms are not only grouped into myeloproliferative (MPN) and myelodysplastic neoplasms (MDS). There is also a group of haematological disorders that share features of both categories termed myelodysplastic /myeloproliferative neoplasms (MDS/MPN). In this article, we aim to provide a comprehensive and practical guide to WHO-HAEM5 highlighting the genetic alterations that underlie MPN and MDS/MPN. This guide provides an overview of the overlapping commonalities among these entities, as well as their unique characteristics.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/medgen-2024-2003/pdf

Reference24 articles.

1. WHO. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version ahead of print]. WHO classification of tumours series 2022; 5th ed.; vol. 11:[Available from: https://tumourclassification.iarc.who.int/chapters/63].

2. Hehlmann R et al. (2007) Chronic myeloid leukaemia. Lancet. 370(9584): p. 342–50

3. Hochhaus A et al. (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 34(4): p. 966–984

4. Bower H et al. (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 34(24): p. 2851–2857

5. White H E et al. (2022) Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 36(7): p. 1834–1842